Compare Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) vs Prudential PLC (PUK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Maravai LifeSciences Holdings Inc. Class A Common Stock vs Prudential PLC — how do they compare? Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M), while Prudential PLC trades at $23.79 (market cap $29.00B). The key difference: Prudential PLC is far larger — about 29.8× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Prudential PLC pays a 2.33% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days and Prudential PLC for 119 Days on average.
| MRVI | PUK | |
|---|---|---|
Market Cap | $972.90M | $29.00B |
Volume | 4,325,710 | 1,133,946 |
Sector | Health | Financials |
52-Week High | $9.00 | $33.61 |
52-Week Low | $2.83 | $23.54 |
Typical Hold Time | 0 Days | 119 Days |
Enterprise Value | $1.08B | $28.54B |
Dividend Yield | — | 2.33% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Prudential Public Limited Company (PUK) trades at $23.81, down 0.25% on the day, with mixed technical signals showing bearish moving averages but oversold RSI readings. The company demonstrates strong fundamentals with $27.39B revenue in 2025, 12.27% net income margin, and attractive valuation metrics including an 8.38 P/E ratio. Recent earnings show two beats and two misses in the last four quarters, while analyst sentiment remains moderately positive with 50% buy ratings.
PUK presents a compelling value opportunity with strong profitability and growth in Asian markets, though near-term technical weakness and emerging market exit execution risks warrant caution. The stock's current valuation discount to peers and consistent dividend payments provide downside protection, while strategic refocusing on core markets could drive long-term shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →About Prudential PLC
Prudential is an Asia and Africa health and life insurance business and is focused on long-term savings. The business is increasingly focusing on digital offerings and creating strong brand equity and relationships with customers of its products through these.
Read more on PUK →
